Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as ABT-333 Tablet
ABT-333 · 4 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Group 1 | EXPERIMENTAL | Single dose of 400 mg |
| Group 2 | EXPERIMENTAL | Single dose of 800 mg after safety evolution of Group I |
| Group 3 | EXPERIMENTAL | Single dose of 1200 mg after safety evolution of Group 2 |
| Group 4 | EXPERIMENTAL | Single dose of 1600 mg after safety evolution of Group 3 |
| Group 5 | PLACEBO_COMPARATOR | Single dose of placebo |
| 1. ABT-333 Tablet | ACTIVE_COMPARATOR | Three 400mg ABT-333 Tablets, BID |
| 2. ABT-333 Tablet | ACTIVE_COMPARATOR | Four 400mg ABT-333 Tablets, BID |
| 3. Placebo | PLACEBO_COMPARATOR | Three or four placebo tablets, BID |
| 1. ABT-333 Capsule vs ABT-333 Tablet | ACTIVE_COMPARATOR | 400mg ABT-333 Tablet, QD, single dose vs eight 50mg ABT-333 Capsules, QD, single dose |
| 1 | OTHER | Healthy volunteers, receiving daily doses of 200 mg ABT-333 or placebo, BID for 10 days; and on Study Day 11 receiving a single dose of 200 mg ABT-333 or placebo + 400 mg ketoconazole |
| 2 | OTHER | Healthy volunteers, receiving 400 mg ABT-333 or placebo, BID |
| 3 | OTHER | Healthy volunteers, receiving 600mg ABT-333 or placebo, BID |
| 4 | OTHER | Healthy volunteers, receiving 1000mg ABT-333 or placebo, BID |
| 5 | OTHER | Healthy volunteers, receiving 1600mg ABT-333 or placebo, BID\* \*After review of the data from previous groups, and in accordance with the protocol, this arm was not dosed. |
| Name | Type | Description |
|---|---|---|
| ABT-333 | DRUG | Tablet, see arms for interventional description |
| Placebo | DRUG | Tablet, see arms for interventional description. |
| ABT-333 Tablet | DRUG | See Arm Description for more information. |
| ABT-333 Capsule | DRUG | See arm description for more information |
| ketoconazole | DRUG | Tablet, see arms for intervention description |
Inclusion Criteria: * Subject has provided written consent. * Subject is in general good health. Exclusion Criteria: * See above for main selection criteria.
Top 19 of 30 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Pfizer Inc. | PFE | 7 | PHASE3 | VLA15, Prevenar 20, 13vPnC, ATM-AVI, PG4 |
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE3 | PCV21 |
| GSK plc Sponsored ADR | GSK | 4 | PHASE2 | Penmenvy, iNTS-TCV, Strep A vaccine, Pan-Salmonella vaccine |
| Grifols, S.A. Sponsored ADR Class B | GRFS | 1 | PHASE3 | Xembify |
| CorMedix Inc. | CRMD | 1 | PHASE3 | DefenCath |
| Sinovac Biotech Ltd. | SVA | 4 | PHASE3 | Sinovac PCV24, Group ACYW135X Meningococcal Conjugate Vaccine, Group ACYW135 Meningococcal Conjugate Vaccine |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | EDI048 |
| Innoviva, Inc. | INVA | 3 | PHASE2 | Eravacycline, Sulbactam-durlobactam |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| Hoffmann-La Roche | RHHBY | 1 | PHASE3 | Baloxavir Marboxil |
| Merck & Co., Inc. | MRK | 2 | PHASE1 | V118C |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD7760 |
| BioNTech SE Sponsored ADR | BNTX | 1 | PHASE1 | BNT163 |
| 60 Degrees Pharmaceuticals, Inc. | SXTP | 1 | PHASE2 | Tafenoquine |
| Tarsus Pharmaceuticals, Inc. | TARS | 1 | PHASE2 | TP-05 |
| Moderna, Inc. | MRNA | 1 | PHASE2 | mRNA-1982 |
| AN2 Therapeutics, Inc. | ANTX | 1 | PHASE2 | Epetraborole |
| Emergent BioSolutions Inc. | EBS | 4 | - | AIGIV/kg |
| Phathom Pharmaceuticals, Inc. | PHAT | 1 | - | Vonoprazan |
ABT-333 is an investigational small molecule developed by Abbott Laboratories for the treatment of hepatitis C virus (HCV) infection. It has been studied in Phase 1 clinical trials, primarily in healthy adult volunteers, to evaluate safety, tolerability, and pharmacokinetics. It is not yet approved for any indication.
ABT-333 is being developed for the treatment of hepatitis C virus infection. All completed trials to date have enrolled healthy volunteers rather than patients with chronic HCV, focusing on safety, tolerability, and pharmacokinetic profiling. It remains an investigational agent and is not approved for clinical use.
ABT-333 is developed by Abbott Laboratories, which trades under the ticker ABT. Abbott conducted the Phase 1 clinical program for the compound, including studies in the United States and Japan.
ABT-333 is in Phase 1 clinical development. Four Phase 1 trials have been completed, with no active trials ongoing. The studies enrolled a total of 142 participants and were randomized, double-blind, and placebo-controlled.
ABT-333 has been evaluated in four completed Phase 1 trials: NCT00919490, NCT00909636, NCT00895102, and NCT00768690. These studies assessed single and multiple ascending doses, bioavailability of the tablet versus capsule formulation, and pharmacokinetics in healthy volunteers.
Yes, ABT-333 Tablet refers to the tablet formulation of ABT-333. One Phase 1 trial, NCT00895102, specifically compared the bioavailability of the ABT-333 tablet against the first-in-human capsule formulation.